Allan MD - Prime Medicine, Chief Officer
| PRME Etf | USD 2.84 0.24 9.23% |
| Age | 50 |
| Phone | 617 564 0013 |
| Web | https://primemedicine.com |
Prime Medicine, Management Efficiency
The company has return on total asset (ROA) of (0.4651) % which means that it has lost $0.4651 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1435) %, meaning that it created substantial loss on money invested by shareholders. Prime Medicine,'s management efficiency ratios could be used to measure how well Prime Medicine, manages its routine affairs as well as how well it operates its assets and liabilities.Similar Fund Executives
| Showing other executives | One Year Return | ||
| Linea Aspesi | Editas Medicine | 55 | |
| Deborah Palestrant | Relay Therapeutics | N/A | |
| JD Esq | Caribou Biosciences | 70 | |
| Chad Cowan | Century Therapeutics | N/A | |
| Ariel Hurley | Blueprint Medicines Corp | 51 | |
| Baisong MD | Editas Medicine | 60 | |
| CPA CFA | Royalty Pharma Plc | N/A | |
| Douglas CPA | Century Therapeutics | N/A | |
| Gopi Shanker | Beam Therapeutics | N/A | |
| Cristi Barnett | Editas Medicine | N/A | |
| Susan Kim | Crispr Therapeutics AG | N/A | |
| Derek Hicks | Intellia Therapeutics | 50 | |
| Jeanne Gray | Relay Therapeutics | N/A | |
| Amy CFA | Caribou Biosciences | N/A | |
| James Reddoch | Royalty Pharma Plc | 54 | |
| Farah Anwar | Sana Biotechnology | N/A | |
| Gregory Whitehead | Editas Medicine | N/A | |
| MD MBA | Ocean Biomedical | 59 | |
| Reigin Zawadzki | Caribou Biosciences | N/A | |
| Robin Andrulevich | Sana Biotechnology | 58 | |
| James JD | Crispr Therapeutics AG | 53 | |
Management Performance
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.47 |
Prime Medicine, Common Money Managers
| David Liu, CoFounder Board | ||
| Meredith Goldwasser, Senior Operations | ||
| Andrew MD, CoFounder Platform | ||
| Richard Brudnick, Chief Officer | ||
| Keith MD, CEO and President | ||
| Ann Lee, Chief Officer | ||
| Karen JD, Senior Affairs | ||
| Allan MD, Chief Officer | ||
| Niamh Alix, Chief Officer | ||
| Keith Gottesdiener, CEO and Presidentident |
Prime Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is Prime Medicine, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.47 | ||||
| Operating Margin | (259.48) % | ||||
| Current Valuation | 238.22 M | ||||
| Shares Outstanding | 131.16 M | ||||
| Shares Owned By Insiders | 23.90 % | ||||
| Shares Owned By Institutions | 58.97 % | ||||
| Number Of Shares Shorted | 17.3 M | ||||
| Price To Earning | 14.40 X | ||||
| Price To Book | 1.97 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Prime Etf
Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.